Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AssigneeSequoia Sciences, Inc.
InventorsGary Eldridge, Steven M. Martin
Life of this patent
Estimating the term…
Abstract
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
Claims27
1-36. (canceled)
A method of inducing the production of antibodies against FimH in a human, the method comprising administering a vaccine composition comprising (i) an effective amount of an antigen of FimCH or truncated FimH, and (ii) an adjuvant formulation containing about 20 micrograms to about 50 micrograms of one or more of the following compounds:
- or mixtures thereof, or pharmaceutically acceptable salts thereof.
The method of claim 1, wherein the compound comprises
A method of inducing the production of antibodies against FimH in a human, the method comprising (i) an effective amount of an antigen of FimCH or truncated FimH, and (ii) an adjuvant formulation containing about 20 micrograms to about 50 micrograms of one or more of the following compounds:
- or mixtures thereof, or pharmaceutically acceptable salts thereof.
The method of claim 13, wherein the adjuvant formulation comprises
A vaccine composition comprising (i) an effective amount of an antigen of FimCH or truncated FimH, and (ii) an adjuvant formulation containing about 20 micrograms to about 50 micrograms of one or more of the following compounds:
- or mixtures thereof, or pharmaceutically acceptable salts thereof.
A vaccine composition comprising (i) an effective amount of an antigen of FimCH or truncated FimH, and (ii) an adjuvant formulation containing about 20 micrograms to about 50 micrograms of one or more of the following compounds:
- or mixtures thereof, or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.